BioSpace News Archive

Biotech companies recently have many openings for technical writer jobs because other than just creating the product they need someone to explain the working as well.

Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.

3M Health Information Systems has introduced a new technology platform that allows health care providers and payers to prioritize care and allocate resources for high-risk individuals and patient populations.

Heathrow Scientific, LLC celebrates 25 years as a global manufacturer of bench top equipment and lab essentials.

For the eighth consecutive year, St. Jude Children’s Research Hospital® earned the 2021 Health Nonprofit Brand of the Year distinction in the latest national Harris Poll EquiTrend® Study, which also named St. Jude the Most Trusted Brand and the Most Loved Brand among health nonprofits.

New Orders, Production & Employment Growing; Supplier Deliveries Slowing at Faster Rate; Backlog Growing; Raw Materials Inventories Growing; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

Mr. McKee will also continue in his responsibilities as Chairman of the Board of Directors of the Company.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of COPIKTRA

Both are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.cardiolrx.com.

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME regulatory filings expected by year-end FY2021, the company will outline plans for organic and sustainable revenue growth over the next several years.